Meanwhile, initial metastasis biomarkers, such as VEGF and MMP-9, revealed that combination treatments of MIP, ACA, and CDDP against highly metastatic tumor models successfully downregulated these protein levels. This evidence concerns the gene MIP and neoplasm.